A similar magnitude of erythropoiesis has been reported with SGLT2 inhibitors in a subpopulation of diabetes patients with normal kidney function.9,14 However, our findings are the first, to our knowledge, to show that canagliflozin improves erythropoiesis, including hemoglobin and hematocrit levels, in patients with impaired kidney function and anemia of chronic kidney disease. The gene discussed is SLC5A2; the disease is anemia (phenotype).